Hologic (Nasdaq: HOLX), a $3.4b developer of diagnostics, imaging systems, surgical products, and light-based aesthetic and medical treatment platforms for women is buying Acessa Health, the developer of the Acessa ProVu system, a laparoscopic device combining radiofrequency ablation and advanced intra-abdominal ultrasound to treat benign uterine fibroids (tumors). The ProVu procedure, addressing fibroids within the uterine wall and on the uterine surface within the abdomen, complements Hologic’s existing MyoSure® products, which are used for hysteroscopic removal of fibroids found in the uterine cavity. The Acessa ProVu represents a minimally invasive alternative to a hysterectomy, surgical removal of the uterus, or myomectomy, surgical removal of fibroids. The incidence of uterine fibroids among women is between 50% and 60%, increasing to approximately 70% by age 50. Accessa is projected to generate sales of $13m in 2021. Deal terms – $80m upfront plus additional milestones.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Diagnostics